Jingtao Gu

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Qingyong Ma · 5 shared papers, 2022–2025 · strength 1.02
   • Paper A qualitative study on the disease coping experiences of pancreatic cancer patients and their spouses. DOI 10.1038/s41598-024-69599-7↗
   • Paper NEAT1 promotes the perineural invasion of pancreatic cancer via the E2F1/GDNF axis. DOI 10.1016/j.canlet.2025.217497↗
   • Paper Correction to: Resveratrol inhibits the expression of RYR2 and is a potential treatment for pancreatic cancer. DOI 10.1007/s00210-023-02499-1↗
2. Zheng Wang · 3 shared papers, 2022–2023 · strength 0.50
   • Paper Correction to: Resveratrol inhibits the expression of RYR2 and is a potential treatment for pancreatic cancer. DOI 10.1007/s00210-023-02499-1↗
   • Paper Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of panc… DOI 10.1016/j.canlet.2022.215976↗
   • Paper Resveratrol inhibits the expression of RYR2 and is a potential treatment for pancreatic cancer. DOI 10.1007/s00210-022-02203-9↗
3. Weikun Qian · 2 shared papers, 2023–2025 · strength 0.40
   • Paper NEAT1 promotes the perineural invasion of pancreatic cancer via the E2F1/GDNF axis. DOI 10.1016/j.canlet.2025.217497↗
   • Paper Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of panc… DOI 10.1016/j.canlet.2022.215976↗
4. Guotai Wang · 2 shared papers, 2022–2023 · strength 0.34
   • Paper Correction to: Resveratrol inhibits the expression of RYR2 and is a potential treatment for pancreatic cancer. DOI 10.1007/s00210-023-02499-1↗
   • Paper Resveratrol inhibits the expression of RYR2 and is a potential treatment for pancreatic cancer. DOI 10.1007/s00210-022-02203-9↗
5. He Jiang · 2 shared papers, 2022–2023 · strength 0.34
   • Paper Correction to: Resveratrol inhibits the expression of RYR2 and is a potential treatment for pancreatic cancer. DOI 10.1007/s00210-023-02499-1↗
   • Paper Resveratrol inhibits the expression of RYR2 and is a potential treatment for pancreatic cancer. DOI 10.1007/s00210-022-02203-9↗
6. Ying Xiao · 2 shared papers, 2022–2023 · strength 0.34
   • Paper Correction to: Resveratrol inhibits the expression of RYR2 and is a potential treatment for pancreatic cancer. DOI 10.1007/s00210-023-02499-1↗
   • Paper Resveratrol inhibits the expression of RYR2 and is a potential treatment for pancreatic cancer. DOI 10.1007/s00210-022-02203-9↗
7. Bo Zhang · 1 shared paper, 2024 · strength 0.28
   • Paper A qualitative study on the disease coping experiences of pancreatic cancer patients and their spouses. DOI 10.1038/s41598-024-69599-7↗
8. Liang Han · 1 shared paper, 2024 · strength 0.28
   • Paper A qualitative study on the disease coping experiences of pancreatic cancer patients and their spouses. DOI 10.1038/s41598-024-69599-7↗
9. Jiantao Mo · 1 shared paper, 2025 · strength 0.25
   • Paper NEAT1 promotes the perineural invasion of pancreatic cancer via the E2F1/GDNF axis. DOI 10.1016/j.canlet.2025.217497↗
10. Liang Han · 1 shared paper, 2025 · strength 0.25
    • Paper NEAT1 promotes the perineural invasion of pancreatic cancer via the E2F1/GDNF axis. DOI 10.1016/j.canlet.2025.217497↗
11. Tao Qin · 1 shared paper, 2025 · strength 0.25
    • Paper NEAT1 promotes the perineural invasion of pancreatic cancer via the E2F1/GDNF axis. DOI 10.1016/j.canlet.2025.217497↗
12. Zheng Wang · 1 shared paper, 2025 · strength 0.25
    • Paper NEAT1 promotes the perineural invasion of pancreatic cancer via the E2F1/GDNF axis. DOI 10.1016/j.canlet.2025.217497↗
13. Jiguang Ma · 1 shared paper, 2025 · strength 0.25
    • Paper NEAT1 promotes the perineural invasion of pancreatic cancer via the E2F1/GDNF axis. DOI 10.1016/j.canlet.2025.217497↗
14. Wanxing Duan · 1 shared paper, 2025 · strength 0.25
    • Paper NEAT1 promotes the perineural invasion of pancreatic cancer via the E2F1/GDNF axis. DOI 10.1016/j.canlet.2025.217497↗
15. Simei Zhang · 1 shared paper, 2023 · strength 0.16
    • Paper Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of panc… DOI 10.1016/j.canlet.2022.215976↗
16. Wunai Zhang · 1 shared paper, 2023 · strength 0.16
    • Paper Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of panc… DOI 10.1016/j.canlet.2022.215976↗
17. Zheng Wu · 1 shared paper, 2023 · strength 0.16
    • Paper Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of panc… DOI 10.1016/j.canlet.2022.215976↗
18. Zhengdong Jiang · 1 shared paper, 2023 · strength 0.16
    • Paper Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of panc… DOI 10.1016/j.canlet.2022.215976↗
19. Cancan Zhou · 1 shared paper, 2023 · strength 0.16
    • Paper Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of panc… DOI 10.1016/j.canlet.2022.215976↗
20. Weifan Zhang · 1 shared paper, 2023 · strength 0.16
    • Paper Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of panc… DOI 10.1016/j.canlet.2022.215976↗
21. Pengli Wang · 1 shared paper, 2022 · strength 0.16
    • Paper Resveratrol inhibits the expression of RYR2 and is a potential treatment for pancreatic cancer. DOI 10.1007/s00210-022-02203-9↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.